Quantum BioPharma Ltd.
QNTM
$6.30
$0.060.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.69% | -35.32% | -40.51% | -50.69% | -11.75% |
| Depreciation & Amortization | -80.43% | -85.89% | -88.42% | -67.23% | -44.76% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.10% | -52.89% | -62.54% | -60.81% | -26.11% |
| Operating Income | 16.10% | 52.89% | 62.54% | 60.81% | 26.11% |
| Income Before Tax | 18.18% | 51.11% | 71.36% | 66.78% | 31.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.18% | 51.11% | 71.36% | 66.78% | 31.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 117.08% | 1,123.95% | -- | -- | -- |
| Net Income | 20.66% | 54.82% | 74.00% | 64.39% | 24.17% |
| EBIT | 16.10% | 52.89% | 62.54% | 60.81% | 26.11% |
| EBITDA | 6.47% | 47.28% | 57.59% | 59.71% | 22.18% |
| EPS Basic | 50.12% | 61.89% | 75.07% | 65.12% | 24.91% |
| Normalized Basic EPS | 50.28% | 66.04% | 69.25% | 67.03% | 30.59% |
| EPS Diluted | 50.17% | 61.85% | 75.07% | 65.21% | 24.59% |
| Normalized Diluted EPS | 50.28% | 66.04% | 69.25% | 67.03% | 30.59% |
| Average Basic Shares Outstanding | 72.12% | 15.86% | 3.37% | 2.29% | 1.16% |
| Average Diluted Shares Outstanding | 72.12% | 15.86% | 3.37% | 2.29% | 1.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |